Antibiotic resistance became a global cause for failure of antimicrobial therapy nowadays. Cephalosporin being the class of drugs with broad spectrum of activity and favourable safety profile, many generations of this class nowadays used in clinical practice. The classification from first to fourth generation cephalosporin contain drugs which are effective against gram positive and gram negative organisms. This review describes about the fifth generation of cephalosporin, a new group of drugs in this class which are highly effective against pseudomonas and multidrug resistant staphylococcus aureus. They are less susceptible to development of resistance by microorganisms. The two drugs included in this group are Ceftaboprole and Ceftarolone. The spectrum, mechanisms of action, pharmacokinetics, dosage, drug interactions and clinical uses of these two drugs are described. The fifth generation cephalosporins are an ideal solution for antibiotic resistance in present era.
Nisha A. R., Vanishree H., Mahesh D. M.
Cephalosporium, VAP, HAP, QIDP, FDA, CABP, ABSSI, MRSA, MSSA, ESBL, ABSSSI, CABP
- Anderson, S. D and John G. G. Ceftobiprole: an extended-spectrum anti–methicillin-resistant Staphylococcus aureus cephalosporin. Annals of Pharmacotherapy 42.6 (2008): 806-816.
- Bassetti, Matteo, New antibiotics for bad bugs: where are we? Annals of clinical microbiology and antimicrobials 12.1 (2013): 1.
- Biek, D. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. Journal of antimicrobial chemotherapy. 65.suppl 4 (2010): iv9-iv16.
- Bush, K. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy. Expert opinion on investigational drugs 16.4 (2007): 419-429.
- Corey, G. R. Canvas 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Journal of antimicrobial chemotherapy 65.suppl 4 (2010): iv41-iv51.
- El Solh, Ali. A. Ceftobiprole: a new broad spectrum cephalosporin. Expert opinion on pharmacotherapy 10.10 (2009): 1675-1686.
- Gallagher, J C., and Conan M. Antibiotics simplified. Jones & Bartlett Learning, 2013.
- Ge, Yigong. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrobial agents and chemotherapy .52.9 (2008): 3398-3407.
- Gould, I. M. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? International journal of antimicrobial agents. 37.3 (2011): 202-209.
- Jones, M. E. In?vitro profile of a new β?lactam, ceftobiprole, with activity against methicillin?resistant Staphylococcus aureus. Clinical Microbiology and Infection 13.s2 (2007): 17-24.
- Jorgenson, M.R., Daryl D. D, and Peggy L. C. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Annals of Pharmacotherapy. 45.11 (2011): 1384-1398.
- Kanafani, Z. A and G. Ralph Corey. Ceftaroline: a cephalosporin with expanded Gram-positive activity. (2009): 25-33.
- Laudano, J. B. "Ceftaroline fosamil: a new broad-spectrum cephalosporin. Journal of antimicrobial chemotherapy.66.suppl 3 (2011): iii11-iii18.
- Lichtman, S. M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. European journal of cancer 43.1 (2007): 14-34.
- Mehta, A. A. A pilot programme of MRSA surveillance in India. (MRSA Surveillance Study Group). Journal of Postgraduate medicine 42.1 (1996): 1.
- Noel, G. J. Clinical profile of ceftobiprole, a novel β-lactam antibiotic. Clinical Microbiology and Infection .13 (2007): 25-29.
- Pratt, R. F. Substrate specificity of bacterial DD-peptidases (penicillin-binding proteins). Cellular and Molecular Life Sciences. 65.14 (2008): 2138-2155.
- Rizvi, M. W. Ceftobiprole-A novel cephalosporin to combat MRSA. Eastern Journal of Medicine 16.1 (2011): 1.
- Roger, G. Little II. "Identification of novel antimicrobial agents using metabolic oxidation-reduction indicator dyes." U.S. Patent No. 6,436,660. 20 Aug. 2002.
- Steed, M. E., and Michael J. R. "Ceftaroline: A New Cephalosporin with Activity against Resistant Gram?Positive Pathogens. “Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy30.4 (2010): 375-389.
- Van Wart, S. A., Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community?acquired bacterial pneumonia. The Journal of Clinical Pharmacology 53.11 (2013): 1155-1167.
- Von Nussbaum, F. Antibacterial natural products in medicinal chemistry - exodus or revival?" Angewandte Chemie International Edition. 45.31 (2006): 5072-5129.
- Walker, R. C. "The fluoroquinolones." Mayo Clinic Proceedings. Vol. 74(10) Elsevier, 1999.
- Walsh, C. "Molecular mechanisms that confer antibacterial drug resistance." Nature. 406.6797 (2000): 775-781.
|Published in :
||Volume 3 | Issue 1 | January-February - 2017
|Date of Publication
Cite This Article
Nisha A. R., Vanishree H., Mahesh D. M., "Fifth generation cephalosporins: Drugs to overcome antibiotic resistance", International Journal of Scientific Research in Science, Engineering and Technology(IJSRSET), Print ISSN : 2395-1990, Online ISSN : 2394-4099, Volume 3, Issue 1, pp.228-232, January-February-2017.
URL : http://ijsrset.com/IJSRSET173130.php